To improve the CD33 | CD16b construct and address matters that include relapse from single-antigen-loss in AML, blood cancers beyond AML, and protection of HSCs, we created proof-of-concept Tmod designs that incorporate 2 additional antigen-binding domains directed at SPN and CLEC9A placed in tandem with the CD33 scFv for the SPN activator and the CD16b scFv for the CLEC9A blocker. This evidence concerns the gene CLEC9A and hematopoietic and lymphoid system neoplasm.